Search academic texts

Registration Number

0223U000567, 0120U101112 , R & D reports

Title

Experimental substantiation and clinical and immunological evaluation of new approaches to the use of mucosal vaccination with microbial and viral antigens in infectious and inflammatory diseases of the upper respiratory tract

popup.stage_title

Head

Zabolotnyi Dmytro I., Доктор медичних наук
Melnykov Oleh F., Доктор медичних наук

Registration Date

12-01-2023

Organization

State Institution "O. S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine"

popup.description2

Conducted studies have proven that in patients with chronic inflammatory diseases of the upper respiratory tract in the remission phase, vaccination against both influenza A and B viruses and mucosal antibacterial vaccine causes a significant decrease in the number and suppression of exacerbations of the main disease within 6 months after vaccination, a decrease in cases of acute respiratory viral infections. The paper shows that in patients with chronic inflammatory diseases of the upper respiratory tract, a standard one-time vaccination against influenza A and B helps to stimulate or normalize the quantitative and functional characteristics of the factors of innate local and systemic immunity (polymorphonuclear leukocytes, natural killer cells, etc.) ) and increases the number of patients who had antibodies to hemagglutinins of viruses in clinically significant titers in the immediate period (up to 3 months) after vaccination. The transferred disease or vaccination against the SARS Cov-2 virus causes reliable suppression of the activity of a number of mechanisms of systemic immunity. A decrease in the level of ϒ-interferon, the concentration of CYC, the number of CD8 lymphocytes and the functional activity of PCC in the blood of coronavirus-positive patients with chronic diseases of the upper respiratory tract indicates the depressant role of coronavirus antigens and the formation of immunodeficiency, against the background of which the stimulation of immune mechanisms with an additional mucosal vaccine (OM-85) is accompanied by a reduced immune response to microbial antigens. Ways of increasing the effectiveness of intranasal vaccination against influenza have been studied under the conditions of an experiment on animals. The effectiveness and expediency of using cerium dioxide nanoparticles to enhance the effect of intranasal administration of the influenza vaccine and to correct a weak immune response has been proven.

Product Description

popup.authors

Belousova Alla O.
Volosevich Larysa I.
Gogunska Inna Volodymyrivna
Zaets Tetiana A
Zabolotna Diana D.
Kryvokhatska Liudmyla D.
Peleshenko Natalia O.
Rylska Oxana G.
Savchenko Tamila D.
Sambur Maryna B.
Sidorenko Tetiana V.
Smagina Tetyana V.
Timchenko Marina D.
Timchenko Sergiy V.
Faraon Inna V

popup.nrat_date

2023-01-12